New life in a sleeper: Thalidomide and Crohn's disease

Gastroenterology

Volumn 117, Issue 6, 1999, Pages 1485-1488

  Sands, B E ^a   Podolsky, D K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

CROHN DISEASE; DRUG CONTROL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TERATOGENICITY;

EID: 0032732395     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0016-5085(99)70299-4     Document Type: Editorial

References (32)

1. FO. Kelsey Historical perspective. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
2. BA. Hill Characterization of embryopathy risks. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
3. EP Sampaio G Kaplan A Miranda JA Nery CP Miguel SM Viana EN. Sarno The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum J Infect Dis 168 1993 408 414
4. J. Woodcock Current issues and overview. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
5. PM Parker N Chao A Nademanee MR O'Donnell GM Schmidt DS Snyder AS Stein EP Smith A Molina DE Stepan A Kashyap I Planas R Spielberger G Somlo K Margolin K Zwingenberger K Wilsman RS Negrin GD Long JC Niland KG Blume SJ. Forman Thalidomide as salvage therapy for chronic graft-versus-host disease Blood 86 1995 3604 3609
6. O Gutierrez-Rodriguez P Starusta-Bacal O Gutierrez-Montes Treatment of refractory rheumatoid arthritis—the thalidomide experience J Rheumatol 16 1989 158 163
7. MS Hecker MG. Lebwohl Recalcitrant pyoderma gangrenosum: treatment with thalidomide J Am Acad Dermatol 38 1998 490 491
8. M Carlesimo S Giustini A Rossi P Bonaccorsi S. Calvieri Treatment of cutaneous and pulmonary sarcoidosis with thalidomide J Am Acad Dermatol 32 1995 866 869
9. AL Holm KE Bowers TO McMeekin AA. Gaspari Chronic cutaneous lupus erythematosus treated with thalidomide Arch Dermatol 129 1993 1548 1550
10. TG Berger C Hoffman MD. Thieberg Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide J Am Acad Dermatol 33 1995 837 838
11. LN Alexander CM. Wilcox A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers AIDS Res Hum Retroviruses 13 1997 301 304
12. G Reyes-Teran JG Sierra-Madero V Martinez del Cerro H Arroyo-Figueroa A Pasquetti JJ Calva GM. Ruiz-Palacios Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial AIDS 10 1996 1501 1507
13. RA Soler M Howard NS Brink D Gibb RS Tedder D Nadal Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide [discussion 504–505] Clin Infect Dis 23 1996 501 503
14. PT Postema P den Haan PM van Hagen M van Blankenstein Treatment of colitis in Behçet's disease with thalidomide Eur J Gastroenterol Hepatol 8 1996 929 931
15. E Burton M. Prados New chemotherapy options for the treatment of malignant gliomas Curr Opin Oncol 11 1999 157 161
16. AR Wettstein AP. Meagher Thalidomide in Crohn's disease Lancet 350 1997 1445 1446
17. MF Waters AB Laing A Ambikapathy JE. Lennard-Jones Treatment of ulcerative colitis with thalidomide Br Med J 1 1979 792
18. EP Sampaio EN Sarno R Galilly ZA Cohn G. Kaplan Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes J Exp Med 173 1991 699 703
19. DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand DK Podolsky BE Sands T Braakman KL DeWoody TF Schaible SJH. van Deventer Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
20. SR Targan SB Hanauer SJH van Deventer L Mayer DH Present T Braakman KL DeWoody TF Schaible PJ Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease N Engl J Med 337 1997 1029 1035
21. WA Stack SD Mann AJ Roy P Heath M Sopwith J Freeman G Holmes R Long A Forbes MA. Kamm Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease Lancet 349 1997 521 524
22. EA Vasiliauskas LY Kam MT Abreu-Martin PV Hassard KA Papadakis H Yang JB Zeldis SR. Targan An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease Gastroenterology 117 1999 1278 1287
23. ED Ehrenpreis SV Kane LB Cohen RD Cohen SB. Hanauer Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial Gastroenterology 117 1999 1271 1277
24. BJ Scallon MA Moore H Trinh DM Knight J. Ghrayeb Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmem-brane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
25. AL Moreira EP Sampaio A Zmuidzinas P Frindt KA Smith G. Kaplan Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 177 1993 1675 1680
26. DR Moller M Wysocka BM Greenlee X Ma L Wahl DA Flockhart G Trinchiari CL. Karp Inhibition of IL-12 production by thalidomide J Immunol 159 1997 5157 5161
27. MF. McCarty Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis Med Hypotheses 49 1997 123 131
28. C Meierhofer S Dunzendorfer CJ Wiedermann Protein kinase C–dependent effects on leukocyte migration of thalidomide J Infect Dis 180 1999 216 219
29. RJ D'Amato MS Loughnan E Flynn J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
30. JB Zeldis BA Williams SD Thomas ME. Elsayed S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 1999 319 330
31. AA. Mitchell Preventing birth defects due to thalidomide exposure. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
32. S Ochonisky J Verroust S Bastuji-Garin R Gherardi J. Revuz Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients Arch Dermatol 130 1994 66 69